Amplia Therapeutics (ASX:ATX) has completed enrolment for the third cohort in the Phase 1b/2a ACCENT clinical trial for frontline pancreatic cancer patients.

The trial aims to test ascending doses of AMP945 in combination with standard chemotherapy for advanced pancreatic cancer patients.

The company says after one month of treatment, the trial's safety committee will review the clinical data collected and subject to the data will determine the next steps in the trial. 

Shares of Amplia Therapeutics are up 11.11% the past month.